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Abstract 
ErbB1-4 are members of the human epidermal growth factor receptor (EGFR) 
family of tyrosine kinases. ErbB2 has been implicated in many different types of cancer, 
most notably breast cancer. Structural studies reveal that ErbB2 and the Drosophila 
EGFR (DER) share significant similarity. DER is known to be inhibited by Kekkon 1, a 
transmembrane leucine-rich repeat immunoglobulin, or LIG protein. To investigate the 
mechanism of binding to DER and determine if Kek1 could bind ErbB2, an enzyme-linked 
extracellular interaction screen (ELEXIS) was utilized. 
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Figure 1: ErbB 
protein structure. 
Introduction 
According to the Centers for Disease Control and Prevention, cancer is one of 
the leading causes of death in the United States, second only to heart disease (CDC, 
2014). It is known that extracellular domains of cell-surface receptors and ligands 
mediate cell-cell interaction, including adhesion, communication, and signaling initiation 
(Özkan et al., 2013). The epidermal growth factor receptor (EGFR/ErbB) family of 
tyrosine kinases (TK) is correlated to the pathogenesis of several types of cancer, 
including prostate, lung, glioblastoma, and 30% of breast cancers (Kovacs, Zorn, 
Huang, Barros, & Kuriyan, 2015). Further evaluation of this receptor in model organisms 
has shown that the EGFR in Drosophila melanogaster (DER) is able to be bound and 
inhibited by Kekkon1 (Kek1), a founding member of the Drosophila Kekkon family 
(Alvarado, Rice, & Duffy, 2004). The Kekkon family is a family of transmembrane 
proteins composed of an immunoglobulin (Ig) domain and leucine-rich repeats 
(Alvarado et al., 2004). The focus of this project is to investigate the binding of DER and 
ErbB2 to Kek1, with particular focus on the role of DER domain V’s role in the binding 
mechanism.  
 
Epidermal Growth Factor Receptor - Structure and Function 
There are four known human ErbB proteins, EGFR/ErbB-1/HER1, ErbB-2/HER2, ErbB-
3/HER3, and ErbB-4/HER4 and each receptor is essential for 
normal cellular development (Normanno et al., 2006). These 
receptors are composed of an extracellular ligand-binding 
domain, a short helical transmembrane domain, a cytoplasmic 
TK domain, and an approximately 230-amino acid long C-
terminal non-globular tail (Ward & Leahy, 2015). This structure 
is illustrated in Fig. 1. 
Within the extracellular region, the ErbB receptors are 
separated into four subdomains, commonly named domains I-
IV. There are eleven known EGF-like ligands that bind to at 
least one of the receptors, leading to formation of particular 
ErbB homo- or heterodimers (Ward & Leahy, 2015). These ligands are growth factors 
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Figure 2: Ligands known to bind to the ErbB receptor 
family and to which receptors the ligands bind. 
 
 
Figure 3: EGFR Pathway (Okines et al., 
2011) 
specific to ErbB binding that are produced via autocrine (produced by same cell as 
receptor) or paracrine secretion (produced by neighboring cells)(Wilson, Gilmore, Foley, 
Lemmon, & Riese, 2009). The different known ligands and the ErbB receptors they bind 
to are illustrated in Fig. 2. 
The dimerization of the receptors 
then leads to the activation of 
downstream signaling affecting 
cell regulatory systems. As seen 
in Fig. 3, the main process 
activated by dimerization of 
EGFR/ErbB1 is the 
RAS/Raf/MAPK pathway that 
controls downstream regulation of 
cell-cycle progression, 
proliferation, and differentiation 
(Okines, Cunningham, & Chau, 
2011). The MAPK pathway is a signaling module that is highly conserved in order to 
relay information to the nucleus regarding cell maintenance throughout the 
developmental process (Montagut & Settleman, 2009). Dysregulation, excessive 
activation, of this pathway also plays a role in tumor development (Montagut & 
Settleman, 2009).  
The structural components of the EGFR that 
are necessary for ligand binding are 
domains I and III, while domains II and IV 
are involved in the dimerization process 
(Normanno et al., 2006). The ErbB family 
have a particularly unique dimerization and 
activation process. The dimerization process 
is promoted by a dimerization loop when the 
receptors are bound to ligands, inducing the 
conformational change that exposes the 
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Figure 4: Ligand-Induced EGFR Dimerization and 
Activation 
 
Figure 6: Bipartite inhibition 
of DER by Kek1. 
 
Figure 5: Structure of an 
immunoglobulin-like 
domain and leucine-rich 
repeat protein. 
loops for binding (Normanno et al., 2006). This process can be seen in Fig. 4.  
Proper regulation of the ErbB 
tyrosine receptor kinase family is 
essential for the regulation of the 
cell cycle, and as noted above 
when dysregulation occurs, cell 
growth rates may vary, contributing 
to a broad range of cancer types.  
 
 
 
Kekkon Transmembrane Protein Family - Structure and Function 
Prior work in the Duffy lab demonstrated that the extracellular portion of Kek1, 
specifically the LRRs, and domain V of DER are essential for 
their interaction (Alvarado et al., 2004). There are nine LIG 
proteins found in Drosophila and six of the proteins belong to 
the Kekkon family of transmembrane leucine-rich repeat and 
immunoglobulin domain proteins (Maclaren et al., 2004). A 
structural representation of the Kekkon family molecules is 
illustrated in Fig. 5. The method through which Kek1 inhibits 
DER is via a bipartite process. As seen in Fig. 6, the 
inhibition of DER requires 
predominantly the LRRs and 
and transmembrane domain, 
but not Ig or the majority of 
the intracellular domain (Alvarado et al., 2004). The LRRs 
of Kek1 mediate the binding to DER, the transmembrane 
portion promotes the inhibition of the downstream 
signaling, and the PDZ domain bindings site within the 
intracellular domain is responsible for correct trafficking of 
Kek1 (Alvarado et al., 2004; Derheimer et al. 2004).   
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Figure 7: Therapeutic methods of binding inhibition and 
downstream inactivation. 
 
 
A drug called Herceptin is known for inhibiting the overexpression of ErbB2 in people 
that have HER2-positive breast cancer. Herceptin functions by blocking the dimerization 
of the receptors, therefore preventing ErbB2 dependent signaling. This is important for 
the HER2-positive breast 
cancer patients because due 
to ErbB2’s open conformation 
with its dimerization loop 
available for binding, it is able 
to create a homodimer 
without the presence of a 
ligand (Ward & Leahy, 2015). 
The process through which 
Herceptin blocks dimerization can be seen in Fig. 7 as therapeutic type A, which is the 
extracellular binding arm being blocked by the protein or antibody designed for that 
binding site. 
 
Additional structure function studies in the Duffy lab revealed that unlike the human 
ErbB receptors, DER contained an additional extracellular domain – domain V 
(Alvarado et al., 2004). Previous functional data obtained in the Duffy lab determined 
that domain V is the likely domain responsible for the binding to Kek1 (Alvarado et al., 
2004). That lack of domain V in the human ErbB receptors suggests that Kek1 would 
not be able to bind and therefore inhibit the human receptors. In order to evaluate this 
hypothesis and better understand the contribution of domain V to Kek1 binding the goal 
of this work was to use an enzyme linked extracellular interaction screen (ELEXIS) was 
used to assess the binding of ErbB and DER variants to Kek1.  Although ErbB1 was 
originally the receptor chosen to create the chimeras of DER and ErbB by prior MQP 
students, recent structural analysis of the ErbB family suggested ErbB2 was a better 
choice given its structural similarity to DER (Alvarado, Klein and Lemmon, 2009). This 
work revealed that DER, unlike ErbB1, which is in a closed configuration, is actually in 
an open conformation similar to that of ErbB2. Illustrations of the three receptors that 
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were evaluated for the chimera creation can be found in Fig. 8. Based on the visuals in 
Fig. 8, it is clear that ErbB2 was the logical choice for chimera formation.  
 
 
Methods and Materials 
Gateway Cloning 
 The Gateway® cloning system is utilized in the cloning of PCR products, analysis 
of gene function, and creation of expression clones for protein production. The system 
is based on the λ-phage site-specific pathway of recombination between att sites of 
bacterial as well as phage DNA. BP and LR reactions are the basis of the Gateway® 
cloning system and allow for gene sequences to be easily transferred between vectors 
without the need of restriction enzymes. 
 The BP reaction occurs between the gene of interest and the donor vector 
flanked by the attP sites. Recombination occurs between these attP sites and the result 
is an entry clone with the gene of interest flanked by attL sites. The LR reaction is a 
recombination between the attL and attR sites of the entry clone (pENTR) and a 
destination vector flanked by attR sites. The resulting expression clone (pEXPR) 
contains the desired sequence flanked by attB sites that can be expressed in cell 
culture. This process can be seen in an overview of the Gateway® cloning system in 
Fig. 9. The BP and LR reactions are made possible by the clonase enzymes that are 
provided with each kit. Antibiotic resistance and the presence of the ccdB gene in the 
unwanted clone are two selections in this cloning system that result in high efficiency. 
The ccdB gene causes lysis to occur in standard lab strains of E. coli, leading to only 
the proper clone being expressed in the E. coli.  
 
Figure 9: Gateway Cloning System 
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In order to obtain the expression clones, pENTR clones created from the BP 
reactions were used in conjunction with LR reactions with either pUAST-AP (bait) or 
pUAST-Fc (prey) as destination vectors:  7µL of pENTR DNA, 1µL of 150ng/µL pUAST-
tag, and 2 µL of LR clonase mix were incubated for 1 hour at 25˚C. Next, 5 µL of each 
LR reaction were transformed into High Efficiency E. coli cells and plated onto LB + 
Ampicillin plates (50µg/ml) and incubated at 25˚C overnight. Resulting colonies were 
inoculated and mini-prepped utilizing the Qiaprep Spin Mini-prep Kit made by Qiagen®. 
Each expression clone was mini-prepped for use in transfections was purified using 
phenol chloroform precipitation and sent to Eton Bioscience® for sequencing to verify 
the cloning process was complete and correct.  
 
Cell Culture, Transfections, and Expression 
 The Drosophila melanogaster S3 cell line (Stephanie Mohr, DRSC at Harvard 
Medical School) is maintained in two different types of media, Schneider’s 12.5% FBS 
media and Schneider’s Heat Inactivated 10% Ultralow IgG FBS media in either 1:5 or 
1:10 dilutions (dependent on growth rate) in 5 mL cultures under sterile conditions. 
Normal growing conditions for this cell line are 25˚C without CO2 regulation. The 
purpose of the 10% Ultralow IgG FBS media is to ensure minimal immunoglobulin 
presence when completing transfections to reduce possible interactions with the 
secreted proteins of interest.  
 Transfections were performed under sterile conditions and began with the 
seeding of a 6-well cell culture plate. Each well was seeded with the S3 cells in 
Schneider’s 10% Ultralow IgG FBS media in a concentration of 3.125 x 106 cells/mL and 
a final volume of 1.6mL/well. After 24 hours of incubation under normal conditions, the 
cells were then co-transfected with the constitutive Arm-Gal4 driver and the proper 
pUAST responder constructs. At least 6 hours prior to the co-transfection, the 
transfection complex pre-mixes were created as seen in Table 1 (add the EC buffer 
first) and stored at -20 ˚C. 
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Table 1: Transfection Complex Pre-Mix Reagents 
Reagents Amounts 
Arm-GAL4 400 ng 
pUAST 400 ng 
EC Buffer up to 100 µL 
 
Once all items needed for cell culture had been sterilized and placed in the sterile cell 
culture hood, 6.4µL of Enhancer was added to each of the transfection complexes and 
the complex was incubated at room temperature (RT) for 5 minutes. After the 5 minutes, 
40µL of Effectene Transfection Reagent (Qiagen®) was added and the complex was 
incubated at RT for 10 minutes. While the transfection complex formed, the 1.6mL of 
media was aspirated and each well was washed with 2mL of sterile 1X PBS. The 2mL 
of 1X PBS was aspirated and 1.6mL of fresh Schneider’s 10% Ultralow IgG FBS media 
was added to each well. After the 10 minute incubation, 0.6mL of the Ultralow media 
was added to each transfection complex and immediately added to the appropriate well 
drop-wise. The secreted proteins in the media were harvested after 7 days of incubation 
under normal conditions and placed into 15mL conical tubes. The harvested media was 
then centrifuged at 4˚C to pellet any remaining cells. Post-centrifugation, the 
supernatant containing the protein was collected, filtered through a 0.22µm filter into a 
new tube, and aliquoted into 500µL samples. The first aliquot of these samples were 
then verified and quantified via western blot for Fc tagged proteins or alkaline 
phosphatase activity assay for AP tagged proteins. 
 
Quantification of Protein Concentration 
 The quantification of the proteins expressed and harvested from the transfections 
is dependent upon the tag present on the protein. For AP tagged proteins, an alkaline 
phosphatase activity assay in a 96-well plate is utilized to quantify the concentration of 
protein in the aliquoted samples. This is completed utilizing a dilution series (20U/L, 
50U/L, 100U/L, 150U/L, 200U/L) of human placental alkaline phosphatase (hPLAP) as 
the standard, diluted with harvested transfection supernatant that was not introduced to 
a transfection complex. The AP-tagged protein was then diluted with the same 
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transfection supernatant as the standard utilizing a dilution series containing 10µL, 
20µL, 50µL, 75µL of the sample 
respectively. PNPP (100µL/well) 
was the substrate utilized to initiate 
the enzymatic reaction that 
produced colorimetric results that 
were read and recorded every 20 
minutes utilizing the Victor3 plate 
reader and program. The stop 
solution for the reaction is 2N 
NaOH and it was added to the 
active wells after 84 minutes of enzymatic activity. The enzymatic activity of alkaline 
phosphatase stimulates by the PNPP substrate provides an easily visible colorimetric 
response. The response can be seen in Fig. 10, which shows the hPLAP standard in 
row A, sErbB1-Ap dilution in row B, Dscam7 dilutions in rows C and D, and supernatant 
as the negative control in row E.  
The concentrations of the proteins were calculated utilizing the hPLAP standard 
curve and the equation resulting from the linear trend line. The velocity of the sample 
being quantified is utilized to find the concentration in U/L by being substituted in as the 
y value in the equation seen in Fig. 11.  
 
Figure 10: AP activity assay with PNPP enzymatic 
activity occurring. 
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Figure 11: Plot of hPLAP Standard dilution series velocity (A/T) plotted against concentration (U/L) 
Once the concentrations in U/L were identified, the concentrations were multiplied by 
13ng/U in order to determine pg/µL, which was then multiplied by the dilution fact to 
determine the actual amount in the sample. The volume of protein sample necessary for 
an ELEXIS interaction was then determined utilizing the actual amount (pg/µL) and 
multiplying by the 6.8ng required for each interaction. 
 In order to verify and quantify Fc-tagged proteins, a western blot is completed 
(Figure 12). The standard utilized for the western is a dilution of the Fc protein which 
represents 10ng, 20ng, 40ng, and 80ng per well to be utilized in calculating the 
concentration of the samples. The protein samples are normally run in triplicate with 4µL 
of the sample in each well. The sample mixes are made as master mixes and then 
separated into separate Eppendorf tubes for the 5 minute boiling process before loading 
onto the gel in 1X electrophoresis buffer set up within the Bio-Rad electrophoresis 
apparatus. The gel runs for 45 minutes at constant 0.02 amperes. The transfer process 
of the protein onto the nitrocellulose membrane is completed in a sandwich orientation 
within the clamped transfer chamber. The gel and membrane are sandwiched between 
two appropriately sized pieces of filter paper, which is then placed between two pads, all 
of which have been calibrated in the 1X transfer buffer. The transfer process is run for 1 
hour and when complete the membrane is stained with Ponceau stain, rinsed with 
13 
 
dH2O, and then is blocked for 1 hour at RT with 1% Casein (Sigma) dissolved in TBS 
and 0.1% Tween20 (TBST) on a rocking platform. The blot is then washed for 5 minutes 
with TBST and then is incubated overnight (16 hours) at 4˚C with the Gt-anti-Fc primary 
antibody (1:5000 dilution in 1% Casein). After the 16 hour incubation, the blot is washed 
with TBST at RT and then incubated with a 1:20000 dilution of the Ms-anti-Gt secondary 
antibody in 1% Casein for 1 hour at RT on a rocking platform. The blot is once again 
washed with TBST and then the blot is incubated in West Femto HRP Substrate 
solution for 5 mins, excess substrate is wicked off, and then the chemi-luminescence is 
immediately detected and recorded using the Bio-Rad Gel Doc apparatus and Quantity 
One program. 
 
Figure 12: Verification western blot to determine appropriate sized proteins. 
In order to verify that the Quantity One program had calculated the concentrations 
correctly, the Fc standard is plotted in order to create a baseline for the samples, which 
is then utilized to calculate the concentrations.  
ELEXIS: Interaction Assay 
 The ELEXIS assay is a high throughput ELISA-based assay (Figure 13). The 
entire procedure is able to be completed in approximately 24 hours. The assay began 
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with seeding the 96-well plate with 50µL in each well to be utilized with a 1:166.67 
dilution of the anti-AP antibody (Thermo Fischer Scientific) and then incubated for 16 
hours at 4˚C on a rocking platform.  
 
Figure 13: Experimental design of the ELEXIS assay. 
After the 16 hour incubation, the wells were washed with 300µL of PBST (1X PBS + 
0.05% Tween20). The wells were then blocked with 400µL of 1% Casein and incubated 
for an hour and 30 minutes at RT on a rocking platform. During the blocking process, 
the protein mixes were created utilizing 100ng of Fc-Prey, 520µU of AP-bait, 5ng of anti-
Fc-HRP antibody (Jackson Labs), and supernatant up to a total volume of 50µL. After 
the blocking incubation was complete, the block was removed and the protein mixes 
were added to the appropriate wells. The plate was then covered with aluminum foil and 
incubated at RT on a rocking platform for 4 hours. Next, a working stock of the TMB 
Ultra HRP Substrate (Thermo Fischer Scientific) was obtained and the volume in the 
stock was 100µL per active well on the interaction plate with an additional 1mL of 
substrate to account for pipette error. After the 4 hour incubation, the interaction mixes 
were removed and the wells were washed with PBST while keeping the plate covered in 
foil. After the last wash, the residual PBST was left in the wells until the plate was in the 
gel doc room and ready for the 100µL of HRP substrate to be added to each active well. 
The plate was read and data recorded every 10 minutes at 590nm for 1 hour in the 
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Victor3 plate reader. At the 1 hour time point, 100µL of the 1M H3PO4 stop solution was 
added to the active wells and a last plate reading was completed at 450nm.  
 
Results 
Receptor Variant Construction and Verification  
 Given the structural similarities between DER and ErbB2, and the importance of 
the domain V of DER, two specific variants 
were constructed to initiate a more detailed 
structure/function analysis. The first variant 
created was sDER+ErbB2IV, which is the 
result of swapping domains IV/V of the 
Drosophila receptor with domain IV of the 
human ErbB2 receptor. This was created to 
determine if domain IV of ErbB2 
compensates for the loss of domain V in 
DER. The second variant created was 
sErbB2+DERV, which is the result of 
adding domain V of the fly receptor onto the end of domain IV in the human receptor. 
This was produced in order to test if DER domain V is sufficient to confer binding to 
Kek1.  
 Since the ELEXIS assay utilizes secreted versions of the bait and prey proteins, 
the variants were created using either full-length variants (including transmembrane and 
cytoplasmic domains), previously constructed, as a template or constructed de novo 
(see materials and methods for details). Putative positive pENTR and pEXPR clones 
were then characterized by restriction digest and/or sequencing (Fig. 15 & 16).  
 
Figure 14: Structures of secreted DER/ErbB2 
chimeras. 
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Figure 15: Segment of the sequencing results of sErbB2+DERV-AP. 
 
Figure 16: Restriction digest results of sDER+ErbB2IV-Fc cut with BamHI and run on an agarose 
gel. 
Together the restriction and sequencing analyses confirmed the construction of both 
variant expression clones. The next important component of the project was the 
verification and quantification of the secreted proteins harvested from the transient 
transfections.  
 
Receptor Variant Expression - Validation and Quantification 
The quantification of the protein samples was crucial for the ELEXIS procedure 
because that procedure is highly dependent on the concentrations of tagged proteins 
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utilized. The AP-tagged protein concentrations were calculated utilizing an alkaline 
phosphatase enzymatic activity assay (Materials and Methods). 
 
Table 2: sKek1-AP Concentration Calculations Based on hPLAP Standard. 
 
Table 3: sKek2-AP Concentration Calculations Based on hPLAP Standard. 
sKek2-AP Calculations 
sKek2-
AP 
Volum
e (µL) 
sKek2-
AP 
Velocit
y 
sKek2-
AP 
Amoun
t (U/L) 
Units* 
13ug/U 
sKek2-
AP 
Amoun
t 
(pg/µL) 
Dilutio
n 
Factor 
Actual 
Amoun
t 
(pg/µl) 
Amount 
for 
ELEXIS 
Volu
me 
for 
ELEX
IS 
(µL) 
100 0.101 97.3 97.3*13 1264.9 1 1264.9 6.8 ng/ 
interaction 
5.37
59 
75 0.0761 72.4 72.4*13 941.2 1.33 1251.7
96 
6.8 ng/ 
interaction 
5.43
21 
50 0.052 48.3 48.3*13 627.9 2 1255.8 6.8 ng/ 
interaction 
5.41
48 
 
Tables 2 and 3 show the process through which the concentrations of Kek1-AP 
and Kek2-AP were calculated. The velocity of each sample was determined by plotting 
the absorbance values obtained from the plate reader data versus the time at which that 
absorbance measurement was taken. This process is illustrated in Fig.17 and the 
velocities are the slope of the line within the equation for each sample dilution. The data 
presented suggests that both AP-tagged secreted Kek1 and Kek2 proteins were able to 
be expressed. 
sKek1-AP Calculations 
sKek1-
AP 
Volum
e (µL) 
sKek1-
AP 
Velocit
y 
sKek1-
AP 
Amoun
t (U/L) 
Units* 
13ug/U 
sKek1-
AP 
Amoun
t 
(pg/µL) 
Dilutio
n 
Factor 
Actual 
Amoun
t 
(pg/µl) 
Amount 
for 
ELEXIS 
Volum
e for 
ELEXI
S 
(µL) 
100 0.0903 86.6 86.6*13 1125.8 1 1125.8 6.8 ng/ 
interaction 
6.040
1 
75 0.0119 65.5 65.5*13 851.5 1.33 1132.4
95 
6.8 ng/ 
interaction 
6.004
4 
50 0.0076 45.3 45.3*13 588.9 2 1177.8 6.8 ng/ 
interaction 
5.773
4 
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Figure 17: Plot of sKek1-AP and sKek2-AP dilution series absorbance (405nm) plotted against 
time (mins) 
While the AP tagged proteins could be detected by their associated enzymatic 
activity, the Fc-tagged variants were quantified utilizing the western blot process. The 
samples were run in triplicate in order to determine the average trace densities of the 
bands on the membrane, which were then compared to an Fc standard dilution that was 
included on all western blots.  
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Figure 18: Quantification blot of the Fc tagged variants (sDER+ErbB2IV and sErbB2+DERV). 
The Western blot in Fig. 18 shows the process through which the bands are 
detected utilizing the Quantity One program. The lanes are identified and the lines are 
positioned in the middle of the bands. The brackets are then placed around the bands 
upon selecting the “detect bands” option. The brackets are adjusted to fit the entire 
band within their parameters, and then the standard and samples are selected for 
densitometry analysis. Lane 10 appears to be lower concentration that the other two 
bands in its triplicate, while the rest of the bands appear to have the appropriate 
concentrations for each lane.  
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Figure 19: The Fc standard is plotted to obtain the equation utilized to calculate protein sample 
concentration. 
The equation from the Fc standard plot (Fig. 19) is utilized to calculate the 
concentrations of the protein samples by substituting the x value with each sample’s 
average trace density value. Based on the Westerns, it appears as though the Fc-
tagged variants are of the correct size and able to be expressed. 
 
 
ELEXIS Based Analysis of Receptor Variants 
With all the tagged control and variant proteins in hand, their binding abilities 
were tested using ELEXIS.   Prior work done in the lab indicates that the ability of Kek1 
to bind the DER is approximately 8-10 fold higher than that of Kek2.  As noted above, 
the absence of domain V in the human receptors suggests that they would be incapable 
of binding to Kek1. To investigate this and the relevance of domain V of the fly receptor 
to its binding a preliminary experiment with the variants and wild type receptors was 
carried out.   
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Figure 20: sDER Variants ELEXIS Interaction Data from Time Point 10 Minutes (100-fold increased 
anti-Fc-HRP)  
*Fold difference = (bait/prey absorbances)/(bait/supt absorbances) 
 
The data obtained from the interaction assay showed an 8.9 fold higher 
interaction reading of sKek1-AP/sDER-Fc over sKek2-AP/sDER-Fc, confirming the 
functionality of the ELEXIS assay. In contrast to it’s binding to DER, Kek1 showed 
essentially no interaction with ErbB2 with signals being similar to supernatant alone.  
This is consistent with the putative model for domain V being the critical feature driving 
the binding of Kek1 to DER.  Further support for this was the 6.4 fold higher interaction 
of sKek1-AP/sErbB2+DERV-Fc over sKek2-AP/sErbB2+DERV-Fc. Swapping of domain 
V from DER with domain IV of ErbB2 (sDER+ErbB2IV) seemed to result in a loss of 
specificity and general “stickiness” as the level of background signal with this variant 
with both Kek2 and supernatant only was also high.  
The results from the variant receptor interaction assay show promising results 
regarding binding within the sKek1-AP/sDER-Fc and the sKek1-AP/sErbB2+DERV-Fc 
interactions. The data collected from this assay can be utilized to draw simple 
conclusions, but in order to create a detailed description of the binding of the receptors, 
the assay would need to be completed in triplicate utilizing the appropriate 
concentrations of anti-Fc-HRP antibody. The current interaction set included several 
changes to the protocol, the most important change was the use of 100-fold higher 
concentration of the anti-Fc-HRP antibody. The interaction mix incubation time was then 
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reduced from 4 hours to 1 hour. The post-interaction washes were adjusted from being 
originally only 4 washes of PBST for 1 minute each, to an additional 8 washes with 1X 
PBS for 2 minutes each after the original 4 washes with PBST. The remainder of the 
protocol was followed with no changes being implemented. 
 
 
Discussion 
 The goal of this project was to develop greater insight to the binding of Kek1 and 
the Drosophila EGFR using the ELEXIS approach. To accomplish this, variant 
constructs with both tags (AP and Fc) were generated, the constructs were transfected 
and expressed, the proteins were then verified and quantified utilizing western blotting 
or AP activity assays, and lastly, preliminary data was able to be gathered regarding the 
binding of the variants and wild type receptors (DER and ErbB2) to Kek1 and Kek2.  
 The beginning of the project involved creating the necessary constructs in order 
to test the hypothesis of whether DER domain V is necessary to confer binding to Kek1. 
The constructs were created as chimeras of DER and ErbB2 in order to conserve the 
structure of the proteins instead of deleting domains. The first construct created was the 
sDER+ErbB2IV construct, in both the AP and Fc tagged versions. The purpose of this 
variant was to assess whether domain IV, in addition to domain V, of DER is necessary 
for binding and if ErbB2 domain IV is capable of initiating binding to Kek1. The second 
construct created was sErbB2+DERV, also in both tagged versions, to determine if DER 
domain V is sufficient for binding Kek1. These expression clones were verified via 
sequencing and restriction digests. The sequencing was an efficient method of verifying 
that the appropriate construct had been made, especially with the utilization of primers 
that encoded the junction regions. The sequencing results were compared to the 
predicted coding sequence to check for any point mutations. All of these variants have 
been created in construct form, but only the Fc-tagged versions of the variants have 
been expressed and harvested as secreted proteins. This is due to the particular 
orientation of the ELEXIS assay as well as previous data showing that when sDER is 
presented as the bait, the interaction with Kek1 decreases exponentially. This may be 
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due to sDER-AP conferring dimerization, in turn reducing the availability of the receptor 
to bind to Kek1.  
 The western blots that were completed for the variants showed that each of the 
secreted proteins were the expected size (Fig.18).  
 The interaction assay, although a 100-fold higher concentration of the anti-Fc-
HRP antibody was utilized, showed very promising results for the ability of DER domain 
V to confer binding of Kek1 to ErbB2.  Wild type ErbB2 exhibited no binding to Kek1 
(same as background levels), while the binding of ErbB2+ domain V exhibited ~6 fold 
increase in signal relative to wild type ErbB2 and approximately a quarter of the signal 
for DER. The interaction will need to be completed again utilizing proper concentrations 
to determine if the data obtained in this assay can be considered significant.  
 
 
Figure 21: ELEXIS assay 96-well plate post-stop solution addition. 
It is clearly visible on the plate in Fig. 21 that the interaction between Kek1-AP 
and sErbB2+DERV-Fc is much higher than its interaction with sKek2-AP and 
supernatant. The background for the interaction readings were minimally increased in 
24 
 
comparison to the normal procedure results from previously completed assays, which 
allows for generalized conclusion to be made regarding the interaction results. An 
important conclusion to discuss is the 6 fold difference between the interaction of 
sErbB2+DERV-Fc and Kek1-AP versus Kek2-AP. This difference appears to be 
indicative that domain V of DER may be sufficient to confer binding to Kek1, but in 
comparison to the positive control of sKek1-AP/sDER-Fc and the fold over background, 
there is a large difference between the two (Fig. 20). Thus, while the presence of 
domain V on ErbB2 may initiate some binding, it is clear that DER confers a much 
higher rate of binding to Kek1. The basis for this will require further swap and mutant 
receptor variants to be constructed and analyzed. Another interesting result on the 
interaction plate was that of sDER+ErbB2IV-Fc binding to the AP-tagged proteins and to 
supernatant. This suggests that this variant protein is “sticky”, which can be a result of 
the protein binding to the plate leading to a response.  
The next steps for this project are to complete the interaction assay in triplicate 
while following the optimized protocol. Another future experiment could be to swap the 
orientation of the proteins in the interaction by utilizing the both the AP and FC tagged 
versions of all the proteins. Lastly, the potential for developing a cancer therapeutic for 
ErbB2 is likely going to result in the creation of varying versions of Kek1 that bind and 
inhibit ErbB2 in the same process though which Kek1 inhibits DER. In order to get to 
this stage of therapeutic development, greater understanding of the details of Kek1’s 
binding to DER would need to be gained. 
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Appendix A 
ELEXIS interaction assay raw data and calculations 
 
sDER Variant Interaction Assay 4-19-16
Absorbances: Raw Data Ratios: Interaction/(Supt/Bait)
(590nm)
Time: (Supt/Bait) sDER-Fc sDER+ErbB2IV-Fc sErbB2+DERV-Fc sErbB2-Fc sDER-Fc sDER+ErbB2IV-Fc sErbB2+DERV-Fc sErbB2-Fc
5min(start) 0.036 0.337 0.113 0.119 0.036 9.306 3.122 3.278 0.986
10min 0.040 0.789 0.327 0.227 0.042 19.766 8.203 5.691 1.062
15min 0.043 0.903 0.390 0.270 0.045 21.114 9.132 6.314 1.052
20min 0.040 0.789 0.327 0.227 0.042 19.766 8.203 5.691 1.062
Stop (450nm) 0.084 3.298 1.926 1.170 0.099 39.347 22.986 13.966 1.181
Time: (Supt/Bait) sDER-Fc sDER+ErbB2IV-Fc sErbB2+DERV-Fc sErbB2-Fc sDER-Fc sDER+ErbB2IV-Fc sErbB2+DERV-Fc sErbB2-Fc
5min(start) 0.035 0.054 0.105 0.033 0.040 1.527 2.974 0.939 1.130
10min 0.040 0.091 0.250 0.035 0.043 2.293 6.322 0.890 1.090
15min 0.041 0.102 0.298 0.037 0.046 2.510 7.321 0.910 1.140
20min 0.040 0.091 0.250 0.035 0.043 2.293 6.322 0.890 1.090
Stop (450nm) 0.076 0.354 1.412 0.063 0.094 4.639 18.480 0.822 1.230
Labeling:
Time: sDER-Fc sDER+ErbB2IV-Fc sErbB2+DERV-Fc sErbB2-Fc
5min(start) 0.071 0.089 0.034 0.057
10min 0.099 0.195 0.038 0.074
15min 0.108 0.231 0.039 0.066
20min 0.099 0.195 0.038 0.074
Stop (450nm) 0.354 1.092 0.064 0.104
sK1-AP
Time: (Supt/Bait) Dscam7-Fc Dscam1-Fc Dscam7-Fc Dscam1-Fc sDER-Fc sDER+ErbB2IV-Fc sErbB2+DERV-Fc sErbB2-Fc
5min(start) 0.035 0.064 0.037 1.822 1.040 (0.789/0.040) (0.327/0.040) (0.227/0.040) (0.042/0.040)
10min 0.040 0.109 0.041 2.719 1.023
15min 0.041 0.125 0.043 3.025 1.027 sK2-AP
20min 0.040 0.109 0.041 2.719 1.023 sDER-Fc sDER+ErbB2IV-Fc sErbB2+DERV-Fc sErbB2-Fc
Stop (450nm) 0.072 0.533 0.075 7.368 1.042 (0.091/0.040) (0.250/0.040) (0.035/0.040) (0.043/0.040)
sK1-AP
sK2-AP
Supt
sDscam7-AP
sK1-AP
sK2-AP
sDscam7-AP
sErbB2+DERV = sDERVI
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